BioSpecifics Technologies Corp. (NASDAQ:BSTC) Shares Sold by State Street Corp

Share on StockTwits

State Street Corp lessened its holdings in shares of BioSpecifics Technologies Corp. (NASDAQ:BSTC) by 2.1% in the first quarter, according to its most recent filing with the SEC. The firm owned 135,277 shares of the biopharmaceutical company’s stock after selling 2,925 shares during the quarter. State Street Corp owned about 1.84% of BioSpecifics Technologies worth $7,653,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in BSTC. Benjamin F. Edwards & Company Inc. boosted its position in BioSpecifics Technologies by 92.5% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 666 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 320 shares during the period. Meeder Asset Management Inc. lifted its holdings in shares of BioSpecifics Technologies by 131.4% during the first quarter. Meeder Asset Management Inc. now owns 1,627 shares of the biopharmaceutical company’s stock valued at $92,000 after purchasing an additional 924 shares during the last quarter. Citigroup Inc. lifted its holdings in shares of BioSpecifics Technologies by 38.7% during the first quarter. Citigroup Inc. now owns 1,838 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 513 shares during the last quarter. BNP Paribas Arbitrage SA lifted its holdings in shares of BioSpecifics Technologies by 105.7% during the first quarter. BNP Paribas Arbitrage SA now owns 1,907 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 980 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of BioSpecifics Technologies during the first quarter valued at $124,000. Institutional investors own 62.97% of the company’s stock.

Several equities research analysts have recently commented on the company. HC Wainwright upped their target price on BioSpecifics Technologies from $90.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. Zacks Investment Research raised BioSpecifics Technologies from a “strong sell” rating to a “strong-buy” rating and set a $72.00 price target on the stock in a research report on Tuesday, July 14th. Finally, BidaskClub lowered BioSpecifics Technologies from a “hold” rating to a “sell” rating in a research report on Friday.

Shares of BSTC stock opened at $62.66 on Friday. BioSpecifics Technologies Corp. has a fifty-two week low of $42.00 and a fifty-two week high of $69.51. The stock’s 50-day moving average is $62.82 and its two-hundred day moving average is $58.59. The firm has a market cap of $459.92 million, a P/E ratio of 18.82 and a beta of 0.89.

BioSpecifics Technologies (NASDAQ:BSTC) last issued its earnings results on Monday, May 11th. The biopharmaceutical company reported $0.73 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.03). BioSpecifics Technologies had a return on equity of 21.37% and a net margin of 61.80%. The firm had revenue of $9.67 million during the quarter, compared to analyst estimates of $9.20 million. As a group, sell-side analysts forecast that BioSpecifics Technologies Corp. will post 2.21 earnings per share for the current fiscal year.

BioSpecifics Technologies Profile

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brands.

Recommended Story: Market Timing – The Benefits and the Danger

Want to see what other hedge funds are holding BSTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioSpecifics Technologies Corp. (NASDAQ:BSTC).

Institutional Ownership by Quarter for BioSpecifics Technologies (NASDAQ:BSTC)

Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Raymond James Financial Services Advisors Inc. Grows Position in Inovio Pharmaceuticals Inc
Raymond James Financial Services Advisors Inc. Grows Position in Inovio Pharmaceuticals Inc
Raymond James Financial Services Advisors Inc. Makes New $1.01 Million Investment in ProShares Large Cap Core Plus
Raymond James Financial Services Advisors Inc. Makes New $1.01 Million Investment in ProShares Large Cap Core Plus
Raymond James Financial Services Advisors Inc. Boosts Stock Position in Global X FinTech Thematic ETF
Raymond James Financial Services Advisors Inc. Boosts Stock Position in Global X FinTech Thematic ETF
Raymond James Financial Services Advisors Inc. Acquires 12,983 Shares of America Movil SAB de CV ADR
Raymond James Financial Services Advisors Inc. Acquires 12,983 Shares of America Movil SAB de CV ADR
Raymond James Financial Services Advisors Inc. Purchases 611 Shares of SPDR S&P Insurance ETF
Raymond James Financial Services Advisors Inc. Purchases 611 Shares of SPDR S&P Insurance ETF
Raymond James Financial Services Advisors Inc. Sells 16,645 Shares of QTS Realty Trust Inc
Raymond James Financial Services Advisors Inc. Sells 16,645 Shares of QTS Realty Trust Inc


© 2006-2020 Ticker Report